Cargando…
Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study
BACKGROUND: The monoclonal antibody sotrovimab is manufactured to antagonize many types of coronaviruses including the SARS-CoV-2. It is used mainly to treat mild and moderate COVID-19 infection and to prevent the progression of the disease from critical disease to severe. OBJECTIVES: To assess the...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685821/ http://dx.doi.org/10.1186/s43168-021-00104-8 |